← Back to Search

CAR T-cell Therapy

MT-101 for T-Cell Lymphoma (IMAGINE Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Myeloid Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights

IMAGINE Trial Summary

This trial is testing a new cancer treatment made from patients' own blood cells. The cells are modified to target and kill tumor cells, and then infused back into the patient.

Eligible Conditions
  • Cell Therapy
  • Cutaneous T-Cell Lymphoma
  • Peripheral T-Cell Lymphoma
  • Mycosis Fungoides
  • Adoptive Cell Therapy

IMAGINE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and Tolerability of MT-101
Secondary outcome measures
MT-101 cell kinetics in blood
The objective response rate
Other outcome measures
Duration of response (DOR)
Overall survival (OS)
Progression free survival (PFS)

IMAGINE Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2 and Cohort 4Experimental Treatment1 Intervention
MT-101 preceded by conditioning (lymphodepleting) chemotherapy
Group II: Cohort 1 and Cohort 3Experimental Treatment1 Intervention
MT-101

Find a Location

Who is running the clinical trial?

Myeloid TherapeuticsLead Sponsor
1 Previous Clinical Trials
48 Total Patients Enrolled
Michele Gerber, MD, MPHStudy DirectorMyeloid Therapeutics
1 Previous Clinical Trials
48 Total Patients Enrolled

Media Library

MT-101 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05138458 — Phase 1 & 2
Cell Therapy Research Study Groups: Cohort 1 and Cohort 3, Cohort 2 and Cohort 4
Cell Therapy Clinical Trial 2023: MT-101 Highlights & Side Effects. Trial Name: NCT05138458 — Phase 1 & 2
MT-101 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05138458 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many healthcare facilities are currently hosting this research endeavor?

"Currently, 7 medical centres are running this trial. Locations include Miami, Boston and Denver with 4 other locations scattered around the country. To reduce travel costs it is advised that patients choose a site close to them if they wish to be enrolled in the study."

Answered by AI

What is the upper limit of participants for this experiment?

"To successfully complete this trial, 40 qualified individuals must be recruited. Thus far, two of the available locations for participation are Miami Cancer Institute at Baptist Health in Miami, Florida and Dana-Farber/Mass General Brigham Cancer Care in Boston Massachusetts."

Answered by AI

Are there still opportunities for individuals to take part in this trial?

"Affirmative. Clinicaltrials.gov evidences that this clinical trial is currently looking for volunteers, as it was first published on December 15th 2021 and recently updated on October 10th 2022. Forty participants need to be recruited from seven different sites."

Answered by AI

Who else is applying?

What state do they live in?
Virginia
What site did they apply to?
University of Virginia Comprehensive Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
~8 spots leftby Nov 2024